Document registry — page 23
Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.
Documents
-
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in sleep apnoea and obesity over 52 weeks. Primary result: Directionally consistent with the…
High24 Apr 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no…
Very low24 Apr 2025 -
Consultation on the draft of this scoping review, which registers the question: What randomised human evidence exists for BPC-157 in any indication?
22 Apr 2025 -
Consultation on the draft of this intervention review, which registers the question: In adults at elevated cardiovascular risk, what is the effect of a glucagon-like…
20 Apr 2025 -
Long-acting amylin analogue. Amylin receptor agonism at the area postrema promoting meal-related satiation, with a formulation and half-life supporting weekly dosing. The…
Low20 Apr 2025 -
In the population defined for type 2 diabetes mellitus, what is the effect of Mazdutide compared with the comparator used in its contributing trials on the anchor…
Moderate18 Apr 2025 -
Mitochondria-targeted cardiolipin-binding tetrapeptide. Elamipretide binds cardiolipin in the inner mitochondrial membrane, stabilising cristae curvature and the assembly of electron-transport-chain…
Moderate17 Apr 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of Tirzepatide in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low17 Apr 2025 -
Consultation on the draft of this intervention review, which registers the question: In adults with type 2 diabetes, does tirzepatide achieve greater glycaemic and…
16 Apr 2025 -
Consultation on the draft of CEI-MS-06, which specifies the performance a determination must achieve for microbiological quality and states what the resulting figure…
14 Apr 2025 -
In the population defined for heart failure with preserved ejection fraction and obesity, what is the effect of Semaglutide compared with the comparator used in its…
Moderate14 Apr 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of BPC-157 in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary…
Very low13 Apr 2025 -
GLP-1 receptor agonist (exendin-based, short-acting). A short-acting prandial GLP-1 receptor agonist. Its dominant pharmacodynamic effect is marked slowing of gastric emptying, which produces substantial…
Moderate12 Apr 2025 -
What is known about the direction and magnitude of the difference between sponsor-conducted and independently conducted trials, and how should an evidence body treat a…
Moderate11 Apr 2025 -
Observational, phase 3 study of Tirzepatide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low09 Apr 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in hfpef and obesity randomising 731 participants over median 104 weeks. Primary result…
Moderate07 Apr 2025 -
Phase 1 ascending dose, phase 1 study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low06 Apr 2025 -
Consultation on the third version of the semaglutide monograph. The revision incorporates the cardiovascular outcome evidence from SELECT, reported in the New England…
03 Apr 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported…
Very low31 Mar 2025 -
Consultation on the draft monograph for GHRP-2, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
30 Mar 2025 -
In the population defined for immune modulation and adjunctive immunotherapy, what is the incidence of adverse events leading to discontinuation with Thymosin alpha-1…
Moderate30 Mar 2025 -
Consultation on the draft of this safety review, which registers the question: What is the incidence of gastrointestinal adverse events and of discontinuation for…
29 Mar 2025 -
Phase 1 ascending dose, phase 1 study of Amycretin in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Mar 2025 -
Phase 1 ascending dose, phase 1 study of Sermorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Mar 2025 -
Phase 1 ascending dose, phase 1 study of Cagrilintide in obesity over up to 20 weeks. The Institute holds no reported primary result for this record and publishes no…
Very low19 Mar 2025 -
Record of documents ratified in the 2025 Q1 assessment cycle.
18 Mar 2025 -
Residual solvent determination by static headspace gas chromatography
High18 Mar 2025 -
What proportion of the mass lost during treatment with an incretin receptor agonist is lean rather than fat mass, and does it differ from that lost through caloric…
Low17 Mar 2025 -
Consultation on the draft monograph for Dulaglutide, which the assessment committee released for public comment before ratification. The draft grades the compound's…
14 Mar 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in type 2 diabetes randomising 319 participants over 24 weeks. Primary result: A reduction of…
Moderate14 Mar 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of Maridebart cafraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low12 Mar 2025 -
Are the trials in the incretin evidence network sufficiently similar to support indirect comparison?
Moderate11 Mar 2025 -
Phase 1 ascending dose, phase 1 study of Mazdutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low11 Mar 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Retatrutide compared with its…
Moderate10 Mar 2025 -
Randomised, double-blind, placebo-controlled, phase 1 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low06 Mar 2025 -
How is access to incretin-based obesity pharmacotherapy distributed, and what does the pattern of unregulated supply indicate about it?
Low05 Mar 2025 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the effect of Larazotide acetate compared with the comparator used in its…
Moderate01 Mar 2025 -
Custom-synthesis peptides, SARMs, injectable oils and raw materials. 350+ catalogue lines with a custom-synthesis emphasis.
01 Mar 2025 -
Consultation on the draft monograph for GHK-Cu, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
27 Feb 2025 -
Fixed-ratio combination of a long-acting amylin analogue and a GLP-1 receptor agonist. The combination pairs two complementary satiation mechanisms: GLP-1 receptor agonism acting on hypothalamic and hindbrain appetite…
Moderate24 Feb 2025
page 23 of 41